Over the last 7 days, the United States market has experienced a 2.3% decline, yet it remains up by 21% over the past year with earnings forecasted to grow by 19% annually. In this context of fluctuating market conditions, companies with high insider ownership can often signal strong confidence in future growth prospects, making them appealing considerations for investors seeking robust opportunities.

Top 10 Growth Companies With High Insider Ownership In The United States

Name	Insider Ownership	Earnings Growth
Uxin (UXIN)	34.3%	69.4%
Upstart Holdings (UPST)	14.1%	58.5%
KVH Industries (KVHI)	16.2%	146.1%
Karman Holdings (KRMN)	15.6%	52.6%
Forum Markets (FRMM)	32%	127.7%
Duos Technologies Group (DUOT)	10.5%	48.2%
Corcept Therapeutics (CORT)	10.9%	48.9%
Astera Labs (ALAB)	10%	29.4%
AppLovin (APP)	27.2%	22%
Allegiant Travel (ALGT)	10%	133.7%

Underneath we present a selection of stocks filtered out by our screen.

Clearfield (CLFD)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Clearfield, Inc. designs, manufactures, and distributes fiber management, protection, and delivery products both in the United States and internationally with a market cap of approximately $549.69 million.

Operations: Clearfield generates revenue of $148.55 million from its fiber management, protection, and delivery product lines across domestic and international markets.

Insider Ownership: 18.5%

Clearfield, Inc. is poised for significant growth with its revenue expected to increase over 20% annually, outpacing the broader US market. Despite a recent dip in profit margins and substantial insider selling, the company's strategic partnerships and innovative fiber solutions enhance its growth potential. Collaborations like those with VoltServer aim to advance power initiatives for 5G networks while projects in the British Virgin Islands showcase Clearfield's efficient deployment capabilities amidst challenging conditions.

BillionToOne (BLLN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BillionToOne, Inc. is a precision diagnostics company that focuses on quantifying biology to develop molecular diagnostics, with a market cap of $4.63 billion.

Operations: The company's revenue is primarily derived from its Medical Labs & Research segment, which generated $354.54 million.

Insider Ownership: 11.1%

BillionToOne, Inc. demonstrates strong growth potential with forecasted revenue and earnings growth surpassing the US market averages. Despite recent share price volatility, the company has raised its 2026 revenue guidance significantly. The launch of Unity Confirm, a non-invasive prenatal test, could drive future growth by addressing unmet medical needs. Recent inclusion in the S&P Health Care Services Select Industry Index highlights its industry relevance and may enhance investor interest.

Precigen (PGEN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies for diseases in immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $1.92 billion.

Operations: The company's revenue primarily comes from its biotechnology startups segment, which generated $31.60 million.

Insider Ownership: 11.9%

Precigen is positioned for significant growth, with revenue expected to grow at 42.4% annually, outpacing the US market. Despite recent share price volatility and past shareholder dilution, the company trades at 77% below its estimated fair value. Recent FDA approval of PAPZIMEOS for recurrent respiratory papillomatosis offers a unique market opportunity with seven-year exclusivity. While insiders have not made substantial purchases recently, insider selling was significant over the past three months.

Key Takeaways

• Explore the 170 names from our Fast Growing US Companies With High Insider Ownership screener here.
• Contemplating Other Strategies? This technology could replace computers: discover the 30 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.